Since 1975 when the Asilomar Conference convened over recombinant DNA technology and led to the creation of the National Institutes of Health (NIH) Guidelines for Research Involving Recombinant DNA Molecules (recently changed to Guidelines for Research Involving Recombinant and Synthetic Nucleic Acid Molecules), advances in biotechnology and recombinant DNA (rDNA) have necessitated oversight and safety reviews of life sciences research with biological materials through Institutional Biosafety Committee (IBC) oversight in the United States (Berg, Baltimore et al. 1975, Jackson October 1972). Over time from the Guidelines initial implementation, it has become accepted by the scientific and biosafety communities that additional monitoring of non-rDNA biohazards by IBCs should occur (Talbot, King et al. 1981, Dutton and Hochheimer 1982, O’Reilly, Shipp et al. 2012).